参附注射液联合地高辛治疗对心功能不全方向患者疗效及心功能的影响研究

Study on the Effect of Shenfu Injection Combined with Digoxinon Patients with Cardiac Insufficiency and Heart Function

目的 探讨参附注射液联合地高辛治疗对心功能不全方向患者疗效及对心功能的影响。方法 选择2019年1月-2023年6月安徽省广德市中医院心血管内科接收的40例心功能不全患者,按不同治疗方式分作两组,20例接受地高辛治疗作对照组,20例接受参附注射液联合地高辛治疗作观察组,对比两组的血清肌钙蛋白T(cTnT)、N末端脑钠肽前体(NT-proBNP)水平、总有效率及心功能与不良反应。结果 观察组治疗后的cTnT、NT-proBNP水平低于对照组(P<0.05);观察组的总有效率是90.00%,高于对照组的60.00%(P<0.05);观察组治疗后的左室射血分数(LVEF)高于对照组,差异无统计学意义(P>0.05)。结论 参附注射液联合地高辛治疗心功能不全可有效改善血清学指标,进一步提高临床疗效,并提升心功能,且安全性理想。

Objective To investigate the therapeutic effect of Shenfu injection combined with digoxin on patients with cardiac insufficiency and its influence on cardiac function.Methods 40 cases of patients with cardiac insufficiency were received by Cardiovascular Department of Guangde Hospital of Traditional Chinese Medicine from January 2019 to June 2023 were selected,they were divided into two groups according to different treatment methods,20 cases of patients who were treated with digoxin as the control group,20cases of patients who were treated with shenfu injection and digoxin as the observation group,the levels of serum troponin T(cTnT),N-terminal pro brain natriuretic peptide(NT proBNP),total effective rate and cardiac function were compared between the two groups.Results In the observation group,the levels of cTnT and NT proBNP after treatment were lower than the control group(P<0.05).The total effective rate of the observation group was 90.00%,which was higher than 60.00%in the control group(P<0.05).In the observation group,the left ventricular ejection fraction(LVEF)after treatment was higher than the control group,(P<0.05).In the observation group,the incidence of adverse reactions was 13.33%,where was no significant difference compared with 6.67%in the control group(P>0.05).Conclusion Shenfu injection combined with digoxin in the treatment of cardiac insufficiency can effectively improve the serological indicators,further improve the clinical efficacy,as well as enhance cardiac function,with ideal safety.